Term
|
Definition
Brand Dose Freq MOA
Hygroton 6.25-25mg/day 1 Inhibits Na+ and Cl- reabsorption in the distal tubules causing increased excretion of Na+, water, K+, and H+ |
|
|
Term
|
Definition
Brand Dose Freq MOA
Microzide 12.5-25mg/day 1 Inhibits Na+ and Cl- reabsorption in the distal tubules causing increased excretion of Na+, water, K+, and H+ |
|
|
Term
|
Definition
Brand Dose Freq MOA
Lasix 20-80mg/day 2 Inhibits NaCl reabsorption in the ascending Loop of Henle and distal renal tubule, causing increased excretion of Na, Cl, water, Mg, and Ca |
|
|
Term
|
Definition
Brand Dose Freq MOA
Bumex 0.5-4 Inhibits NaCl reabsorption in the ascending Loop of Henle and distal renal tubule, causing increased excretion of Na, Cl, water, Mg, and Ca |
|
|
Term
|
Definition
Brand Dose Freq MOA
Demadex 10-80 Inhibits NaCl reabsorption in the ascending Loop of Henle and distal renal tubule, causing increased excretion of Na, Cl, water, Mg, and Ca |
|
|
Term
|
Definition
Brand Dose Freq MOA
Dyrenium 50-100 2 Interferes with K/Na exchange (active transport) in the distal tubule, cortical collecting tubules and collecting duct by inhibiting Na/K-ATPase |
|
|
Term
|
Definition
Brand Dose Freq MOA
Aldactone 25-50 1-2 Competes with aldosterone for receptor sites in the distal renal tubules. Increases NaCl and water excretion, while conserving K+ and H+ ion. May block the effect of aldosterone on arteriolar smooth muscle |
|
|
Term
|
Definition
Brand Dose Freq MOA
Capoten 12.5-150 2-3 Competitive inhibition of angiotensin-converting enzyme (ACE), the enzyme that converts angiotensin I angiotensin II (potent vasoconstrictor). Decreased angiotensin II leads to decreased vasopressor activity and decreased aldosterone secretion |
|
|
Term
|
Definition
Brand Dose Freq MOA
Prinivil, Zestril 10-40(80) 1 Competitive inhibition of angiotensin-converting enzyme (ACE), the enzyme that converts angiotensin I angiotensin II (potent vasoconstrictor). Decreased angiotensin II leads to decreased vasopressor activity and decreased aldosterone secretion |
|
|
Term
|
Definition
Brand Dose Freq MOA
Altace 2.5-10 1-2 Competitive inhibition of angiotensin-converting enzyme (ACE), the enzyme that converts angiotensin I angiotensin II (potent vasoconstrictor). Decreased angiotensin II leads to decreased vasopressor activity and decreased aldosterone secretion |
|
|
Term
|
Definition
Brand Dose Freq MOA
Accupril 10-80 1-2 Competitive inhibition of angiotensin-converting enzyme (ACE), the enzyme that converts angiotensin I angiotensin II (potent vasoconstrictor). Decreased angiotensin II leads to decreased vasopressor activity and decreased aldosterone secretion |
|
|
Term
|
Definition
Brand Dose Freq MOA
Cozaar 50-100 1-2 |
|
|
Term
|
Definition
Brand Dose Freq MOA
Diovan 80-320 1 |
|
|
Term
|
Definition
Brand Dose Freq MOA
Norvasc 5-10 1 Inhibits the influx of calcium through low-voltage (L-type) channels on cell membranes, leading to coronary and peripheral vasodilation |
|
|
Term
|
Definition
Brand Dose Freq MOA
120-360 2 |
|
|
Term
|
Definition
Brand Dose Freq MOA
Cardiazem LA, Cardiazem CD, Dilacor-XR, Tiazac, Taztia XT 120-360 1 |
|
|
Term
|
Definition
Brand Dose Freq MOA
Calan 240-480 3 |
|
|
Term
|
Definition
Brand Dose Freq MOA
Calan SR, Isoptin SR 180-480 1-2 |
|
|
Term
|
Definition
Brand Dose Freq MOA
Levatol 20 1 nonselective beta-adrenergic receptor antagonist |
|
|
Term
|
Definition
Brand Dose Freq MOA
Toprol XL 25-400 1 selective activity on beta(1) adrenoreceptors |
|
|
Term
|
Definition
Brand Dose Freq MOA
Coreg 6.25-25 2 nonselective beta-adrenergic blocking agent with alpha 1-adrenergic blocking activity and no intrinsic sympathomimetic activity |
|
|
Term
|
Definition
Brand Dose Freq MOA
Tenormin 50-100 1 synthetic beta(1)-selective adrenoreceptor blocking agent without membrane stabilizing or intrinsic sympathomimetic activities. It inhibits beta(2)-adrenoreceptors primarily found in bronchial and vascular musculature at higher doses |
|
|
Term
|
Definition
Brand Dose Freq MOA
Cardura 1-16 1 Works on the peripheral vasculature and inhibits norepinehprhine (NE) uptake at α1 receptors in smooth muscle cells, resulting in vasodilation and BP lowering |
|
|
Term
|
Definition
Brand Dose Freq MOA
Apresoline 20-100 2-4 Direct arteriolar smooth muscle relaxant. These agents exert little to no venous vasodilation |
|
|
Term
|
Definition
Brand Initial Dose Target Dose
Lasix® 20-160 |
|
|
Term
|
Definition
Brand Initial Dose Target Dose
Bumex® 0.5-4 |
|
|
Term
|
Definition
Brand Initial Dose Target Dose
Demadex 10-80 |
|
|
Term
|
Definition
Brand Initial Dose Target Dose
Capoten 6.25 mg TID 50 mg TID |
|
|
Term
|
Definition
Brand Initial Dose Target Dose
Vasotec 2.5-5 mg BID 10 mg BID |
|
|
Term
|
Definition
Brand Initial Dose Target Dose
Zestril, Prinivil 2.5-5 mg daily 20-40 mg daily |
|
|
Term
|
Definition
Brand Initial Dose Target Dose
Accupril 10 mg daily 20-40 mg BID |
|
|
Term
|
Definition
Brand Initial Dose Target Dose
Altace 1.25-2.5 mg BID 5 mg BID |
|
|
Term
|
Definition
Brand Initial Dose Target Dose
Monopril 5-10 mg daily 40 mg daily |
|
|
Term
|
Definition
Brand Initial Dose Target Dose
Mavik 0.5-1 mg daily 4 mg daily |
|
|
Term
|
Definition
Brand Initial Dose Target Dose
Aceon 2 mg daily 8-16 mg daily |
|
|
Term
|
Definition
Brand Initial Dose Target Dose
Zebeta 1.25 10 |
|
|
Term
|
Definition
Brand Initial Dose Target Dose
Coreg 3.125 25 |
|
|
Term
| Metoprolol succinate (XL) |
|
Definition
Brand Initial Dose Target Dose
Toprol XL 12.5-25 200 |
|
|
Term
|
Definition
Brand Initial Dose Target Dose
Atacand® 4-8 mg 32 mg once daily |
|
|
Term
|
Definition
Brand Initial Dose Target Dose
Diovan® 40 mg 160 mg BID |
|
|
Term
|
Definition
Brand Initial Dose Target Dose
Inspra 25 50 |
|
|
Term
|
Definition
Brand Initial Dose Target Dose
Aldactone 12.5 25 |
|
|
